Dendritic-Cell Specific Antigen HIV1: Novel Terapi Berbasis Biomolekuler sebagai Imunomodulator pada Penderita HIV Tipe 1

Abstract

Human Immunodeficiency Virus (HIV) infection, either type 1 which is spread worldwide or type 2 which is more isolated in Africa, is still a challenge in the world health sector, including Indonesia. This high HIV rate is important to treat because of the dangers of complications that lurk. The current management and treatment of HIV with the use of antiretrovirals has limitations in terms of therapeutic effects and side effects. The development and discovery of therapeutic modalities that have the potential for a more optimal therapeutic effect is a challenge that continues to be pursued in the treatment of HIV. One of them is the development of dendritic cell-based immunotherapy. This literature review was written systematically on the study reports related to the above from various sources including Google Scholar, PubMed, Research Gate to describe the potential of dendritic cells as immunomodulators in HIV-1 patients. This immunotherapy modality is constructed in the form of a dendritic cellbased vaccine, a cell that plays a role in HIV pathogenesis, which is administered intradermally. The vaccine given will stimulate an immune response and can be used not only as a therapeutic effort in patients but has the potential to be used as prevention